1. United States of America Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
Oncologix Tech, Inc.

Oncologix Tech, Inc.

OCLG
Oncologix Tech, Inc.US flagOther OTC
0.00
USD
- -
- -
73,662.00Market Cap
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
TTM
Revenue per Share
0.27
0.25
0.28
0.15
0.1
- -
- -
- -
- -
- -
- -
- -
0.04
0.02
Basic EPS, GAAP
-1.62
-0.87
-0.88
-0.07
-0.51
-0.46
-0.23
-0.08
-0.02
- -
-0.01
-0.01
-0.01
-0.01
Free Cash Flow per Basic Share
-0.48
-0.31
-0.07
-0.06
-0.05
-0.19
-0.06
- -
- -
- -
- -
- -
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-5.89
-4.87
-4.56
-3.39
-3.54
-3
-2.7
-1.76
-1.27
-1.21
- -
-0.95
-0.47
-0.27
Tangible Book Value per Share
0.68
0.08
0.06
0.02
-0.05
-0.12
-0.12
-0.06
-0.01
-0.01
-0.01
-0.03
-0.02
-0.02
Basic Weighted Avg Shares
4
6
8
11
12
17
20
32
46
48
54
62
103
185
Sales/Revenue/Turnover
1
1
2
2
1
- -
- -
- -
- -
- -
- -
- -
4
5
Operating Margin (%)
-441.07
-266.17
-260.16
-48.7
-514.52
- -
- -
- -
- -
- -
- -
-117.33
-15.55
-12.87
Depreciation Expense
2
2
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-6
-5
-7
-1
-6
-8
-5
-3
-1
- -
- -
-1
-1
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-519.5
-328.34
-316.28
-50.06
-518.37
- -
- -
- -
- -
- -
- -
-267.55
-35.68
-37.98
Working Capital
-1
-1
- -
- -
-1
-2
-2
-1
- -
-1
- -
-1
-2
-3
LT Debt
- -
- -
- -
- -
- -
1
1
- -
- -
- -
- -
1
- -
- -
Total Equity
8
5
- -
- -
-1
-2
-2
-2
-1
-1
-1
- -
-1
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Nov'15
Feb'15
May'15
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
154
210
277
Market Capitalization
- -
1
1

Working Capital

FRC

•

in mil. unless spec.
Nov'15
Feb'15
May'15
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
1
1
1
Inventories
- -
- -
- -
Total Current Liabilities
4
4
5
Payables & Accruals
1
1
1
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-16.59%
-4.46%
84.26%
Free Cash Flow
78.7%
100.78%
496.14%
Net Income, GAAP
65.07%
22.28%
100.78%
Sales/Revenue/Turnover
- -
- -
1,405.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
1
1
1
1
4
2015
1
1
1
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
-0.01
2014
- -
-0.01
- -
- -
-0.01
2015
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Michael A. Kramarz
Full Time Employees
191
Sector
Financial Services
Industry
Shell Companies
Address
1604 West Pinhook Drive Lafayette LA United States of America 70508
IPO Date
Jan 2, 2013
CIK
0000799694
Website
oclghealth.com
Similar Companies
Cantor Equity Partners VI, Inc. Class A Ordinary Shares (CEPS)
Sarissa Capital Acquisition Corp. (SRSA)
Rose Hill Acquisition Corporation (ROSEU)
Medical Care Technologies Inc. (MDCE)
Black Mountain Acquisition Corp. (BMAC-WT)
Welsbach Technology Metals Acquisition Corp. (WTMA)
Business
Oncologix Tech, Inc. (OCLG) operates as a diversified medical holding company focused on healthcare services, medical device manufacturing, and products distribution in the United States. The company provides personal home care services, including daily living assistance, companionship, homemaker services, Alzheimer's care, home care resource planning, and medical care coordination; manufactures and distributes the Toxygen hardware system with disposable speculums and medical-grade tubing for colon cleansing and bowel preparation prior to procedures such as colonoscopies; and offers home medical equipment for sleep and respiratory therapies, including C-PAP and BiPAP oxygen equipment, mask interfaces, personalized treatment plans, monitoring, and support services to skilled nursing facilities, hospitals, assisted living facilities, and home care providers. It also develops biopharmaceutical products such as DNAGO and GenomeGO, which enable clinical genetic testing across more than 20,000 genes covering 7,000+ rare genetic diseases, including cystic fibrosis, Fabry disease, epilepsy, hemophilia, and hereditary cancers. Founded in 1995 and headquartered in Lafayette, Louisiana, with prior references to Los Angeles, California, Oncologix serves domestic markets through segments encompassing personal care services, medical device manufacturing, and medical products distribution via subsidiaries like Advanced Medical Products and Technologies, Esteemcare Inc., and Affordable Medical Inventory Solutions Inc. Recent developments include a 2022 definitive business combination agreement with DNAGO.Ai via reverse merger to integrate its AI-driven genetic testing platform, with plans to rename the combined entity DNAGO while maintaining the OCLG ticker, though completion status remains subject to shareholder approval and customary conditions; earlier acquisition of Dotolo Research Corp. in 2013, enhancing its medical device portfolio with FDA-registered colon hydrotherapy products and appointing Wayne Erwin as CEO; and ongoing pursuit of healthcare service expansions, such as letters of intent for private-pay elderly and veterans services providers, alongside plans for additional acquisitions to boost revenues and EBITDA through home medical equipment synergies. The company, formerly BestNet Communications Corp. until its name change in January 2007, currently functions in part as a non-operating shell pursuing reverse merger opportunities in biotechnology and life sciences.